8-K: Hepion Pharmaceuticals Appoints New Directors
Current Report (8-K)
Hepion Pharmaceuticals, Inc. announced the immediate appointment of Danina Fisher and Gary S. Stetz, II to its Board of Directors.
Summary
- Hepion Pharmaceuticals, Inc. has appointed two new members to its Board of Directors: Danina Fisher and Gary S. Stetz, II.
- These appointments were effective immediately as of July 1, 2026.
- There are no known arrangements or understandings with other parties regarding their selection.
- Gary S. Stetz, II is the son of Gary Stetz, the Interim Chief Executive Officer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it pertains to routine corporate governance changes without immediate financial implications.
Positives
- Expansion of the Board of Directors with new members.
- Immediate effectiveness of the appointments.
Future Outlook
No specific future outlook or guidance was provided in this filing.
Management Comments
- Gary Stetz signed the report as Interim Chief Executive Officer.
Industry Context
StockSavvy.ai notes that board appointments are common for companies seeking to strengthen their governance and strategic oversight, especially in the biopharmaceutical sector where expertise is critical.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Danina Fisher | 2026-07-01 | Board appointment |
| Director | N/A | Gary S. Stetz, II | 2026-07-01 | Board appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Appointment of Danina Fisher and Gary S. Stetz, II as directors. | 2026-07-01 | Strengthens board with new perspectives and potentially relevant expertise. |
Related Party Transactions
- Gary S. Stetz, II is the son of Gary Stetz, the Interim Chief Executive Officer.
Stakeholder Impact
- Shareholders: Potential for improved board oversight and strategic direction.
- Management: Integration of new board members into governance structure.
Key Dates
| Date | Description |
|---|---|
| 2026-07-01 | Date of Board of Directors' approval for the appointment of Danina Fisher and Gary S. Stetz, II as directors. |
| 2026-07-02 | Date of the filing of the Form 8-K report. |
Keywords
Hepion Pharmaceuticals, Board of Directors, Director Appointment, Corporate Governance, SEC Filing, Form 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.